J&J said worldwide sales for Q2 of fiscal 2024 were $22.4 billion, a total increase of 4.3% from $21.5 billion a year earlier. That included operational growth of 6.6% and a negative currency impact of 2.3%.

1. 01

   J&J said worldwide sales for Q2 of fiscal 2024 were $22.4 billion, a total increase of 4.3% from $21.5 billion a year earlier. That included operational growth of 6.6% and a negative currency impact of 2.3%.

2. 02

   The company said Innovative Medicine segment sales for Q2 were $14.5 billion, up 5.5%, and MedTech segment sales were $8.0 billion, up 2.2%. It said segment pre-tax earnings were 37.7% and 13.7% of segment sales, respectively.

3. 03

   J&J said consolidated pre-tax earnings for the first 6 months of fiscal 2024 were $9.5 billion, or 21.6% of sales, compared with $5.0 billion, or 11.8%, a year earlier. Amounts not allocated to segments included talc-related charges of $3.0 billion, compared with $7.1 billion a year earlier.

4. 04

   The company said it issued a total of $6.7 billion in senior unsecured notes during fiscal 2024 in Q2 and used the net proceeds for the Shockwave acquisition, which closed on May 31, 2024, and for general corporate purposes. Net debt was $16.0 billion as of June 30, 2024.

Key figures

Quarter ended June 30, 2024

Revenue

$22.4B

Net income

$4.7B

EPS

$1.93

Gross profit

$15.6B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.